Sirtex Medical and China Grand Pharmaceutical announce landmark drug registration milestone

Thursday 27 August 2020
WOBURN, Mass. (August 27, 2020) –– Sirtex Medical ("Sirtex"), a leading manufacturer of targeted liver cancer therapies, announced today that Sirtex and its shareholders, China Grand Pharmaceutical and Healthcare Holdings Limited (CGP), have been issued a "Notice of Drug Clinical Trial Approval" by the National Medical Products Administration (NMPA) of the People’s Republic of China.

Approval issued to file new drug application for SIR-Spheres® Y-90 resin microspheres in China based on existing clinical trial data.

The notice confirms that SIR-Spheres® Y-90 resin microspheres meet the relevant requirements for drug registration in China. With this confirmation, Sirtex is approved to file a New Drug Application (NDA) in the country.

"We are grateful to the members of CGP, Sirtex China and our Global Regulatory, Quality Assurance, Operations and Medical teams for their dedicated work in achieving this approval from the NMPA and navigating the complex regulatory process," said Kevin R. Smith, Chief Executive Officer of Sirtex. "This is a critical milestone toward allowing us to provide a valuable treatment option to people with liver cancer in China."

The announcement marks an important step in Sirtex’s journey to gain market entry into China, thanks to the company’s collaboration with its shareholder, CGP.

"We are proud of our team’s accomplishment and work to achieve this goal," said Weikun Tang, Ph.D., General Manager of Sirtex China. "We are excited for the opportunity to work together with CGP to bring SIR-Spheres® Y-90 resin microspheres to our country’s patients."

About Sirtex

Sirtex is a global healthcare business with offices in the U.S., Australia, Europe and Asia, working to improve outcomes in people with cancer. Sirtex’s current lead product is a targeted radiation therapy for liver cancer called SIR-Spheres® Y-90 resin microspheres. More than 100,000 doses have been supplied to treat patients with liver cancer at more than 1,300 medical centers in over 45 countries. For more information, visit www.sirtex.com. SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd.


APM-AP-014-08-20


Now leaving sirtex.com

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.

Continue

×

Now leaving sirtex.com

You are about to leave the Sirtex Website. This link is provided to you as a service and will take you to the Sirtex Virtual Booth.

Sirtex is responsible for the content of the Virtual Booth, which is hosted on a website maintained by a third-party. Except for Sirtex’s Virtual Booth experience, please be aware that Sirtex takes no responsibility for the other content of these external sites, nor do we endorse, warrant, or guarantee the products, services or information described or offered on other internet sites.

Continue

×

You are now leaving your current sirtex.com region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.

Continue

×

This content is intended for journalists only

By clicking "Yes" you are confirming that you are a journalist. If you are not a journalist, then please click "Go to Homepage" which will direct you to the Sirtex homepage.

Yes Go to Homepage

Effective May 7, 2021, SIR-Spheres will have the following indication for use:
SIR-Spheres Y-90 resin microspheres are indicated for the treatment of unresectable hepatocellular carcinoma (HCC) and unresectable metastatic liver tumors from primary colorectal cancer in patients refractory to or intolerant of chemotherapy.

Click here to view our Technical Bulletin.

Ok